Highlights of weekly biotech stock moves

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed under a $160 million contract with HHS's Biomedical Advanced Research and Development Authority (BARDA).

Following an early surge to start the week, shares of Durata Therapeutics Inc. (NASDAQ:DRTX) fell $1.93 (12%) to $13.65 on Thursday after FDA approved a competing product and Jefferies' analyst Eun Yang published a note highlighting CMS's denial of a new technology add on payment (NTAP) for Durata's Dalvance dalbavancin, which the company launched in the U.S. in July for acute bacterial skin and skin structure infections (ABSSSIs). The NTAP denial came in a CMS final rule released earlier in the week. FDA approved Orbactiv oritavancin from The Medicines Co. (NASDAQ:MDCO) to treat ABSSSIs late Wednesday...